Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 5/20 | 0.52 |
| ▸ | PADI1 | Q9ULC6 | 5/20 | 0.51 |
| ▸ | PADI4 | Q9UM07 | 5/20 | 0.51 |
| ▸ | PADI2 | Q9Y2J8 | 4/20 | 0.51 |
| ▸ | PDE4A | P27815 | 3/20 | 0.51 |
| ▸ | PADI3 | Q9ULW8 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7925397 | 1.00 | C3AR1 (0.52) | C3AR1PADI1PADI4PADI2PDE4A | |
| SCHEMBL188590 | 1.00 | C3AR1 (0.52) | C3AR1PADI1PADI4PADI2PDE4A | |
| Naphthalene SCHEMBL28216957 | 0.96 | C3AR1 (0.49) | C3AR1PADI1PADI4PADI2PDE4A | |
| Alcohol SCHEMBL2258594 | 0.95 | CA2 (0.49) | C3AR1PADI1PADI4PADI2PDE4A | |
| Alcohol SCHEMBL29029781 | 0.95 | CA2 (0.49) | C3AR1PADI1PADI4PADI2PDE4A | |
| Propane SCHEMBL25417180 | 0.94 | CA2 (0.48) | C3AR1PADI1PADI4PADI2PDE4A | |
| Butane SCHEMBL25420420 | 0.93 | CA2 (0.50) | C3AR1PADI1PADI4PADI2PDE4A | |
| SCHEMBL10946109 | 0.92 | PADI1 (0.60) | C3AR1PADI1PADI4PADI2PDE4A | |
| SCHEMBL158990 | 0.92 | PADI1 (0.60) | C3AR1PADI1PADI4PADI2PDE4A | |
| Ether SCHEMBL9150674 | 0.92 | C3AR1 (0.48) | C3AR1PADI1PADI4PADI2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119096144-A | Rapid diagnostic test for antibiotic resistance and methods of use and preparation thereof | 拜奥普诊断公司 | 2024-12-06 | — | — | CN | claimed |
| CN-111432662-B | Pea protein hydrolysate | 嘉吉公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2024007629-A1 | POLYSACCHARIDE TRYPSIN INHIBITOR AND PREPARATION METHOD THEREFOR | 山东省分析测试中心 | 2024-01-11 | — | — | WO | claimed |
| CN-115068620-A | Pharmaceutical composition capable of reducing generation of arylamine impurities | 天津睿创康泰生物技术有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114196730-A | Method and kit for detecting activity of cysteine protease inhibitor in Chinese tulip tree nectar | 南京林业大学 | 2022-03-18 | — | — | CN | claimed |
| EP-2402037-B1 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | claimed |
| EP-3219335-B1 | COATING COMPOSITION AND MEDICAL DEVICE | TERUMO CORP (JP) | 2018-12-19 | — | — | EP | claimed |
| EP-2813250-B1 | COATING COMPOSITION AND MEDICAL DEVICE | TERUMO CORP (JP) | 2017-05-03 | — | — | EP | claimed |
| US-20150148284-A1 | Controlled Release of Phenolic Opioids | PHARMACOFORE, INC. | 2015-05-28 | — | — | US | claimed |
| EP-2069522-B1 | ENZYME CONTAINING LIQUID AND DELIVERY SYSTEM FOR DETECTION OF ANALYTES ON SURFACES | AGENTASE LLC (US) | 2015-05-27 | — | — | EP | claimed |
| WO-2007140272-A2 | CONTROLLED RELEASE OF PHENOLIC OPIOIDS | PHARMACOFORE, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| US-20040062773-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES INC. | 2004-04-01 | — | — | US | claimed |
| EP-0784469-B1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 2004-03-24 | — | — | EP | claimed |
| US-6610329-B2 | Using acylated amino acid as carrier | EMISPHERE TECHNOLOGIES INC. | 2003-08-26 | — | — | US | claimed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | claimed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0784469-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | claimed |
| US-5284872-A | Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof | SCHWARZ PHARMA AG (DE) | 1994-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020001591-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | C3AR1 249/4885PADI1 3359/4885PADI4 2580/4885 |
| US-20040062773-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | C3AR1 249/4885PADI1 3359/4885PADI4 2580/4885 |
| US-20150148284-A1 | Controlled Release of Phenolic Opioids | OPRK1, OPRM1, OPRD1 | C3AR1 1966/4885PADI1 1751/4885PADI4 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.